The present invention provides a composition comprising ziprasidone useful in the treatment and prevention of schizophrenia and similar psychiatric disorders. In one embodiment, the composition comprises nanoparticulate particles comprising ziprasidone and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a p...

The present invention relates to a process for preparing Ziprasidone of formula I, or a pharmaceutically acceptable salt or a solvate or a hydrate thereof

The present invention provides methods, dosage forms and kits for treating with an effective amount of ziprasidone a CNS disorder in a human when the human is in a fasted state. In one embodiment, the invention relates to a method for treating a CNS disorder in a human, which method comprises administering to the human in a fasted state, a solid oral dosage form comprising an amount of ziprasidone effective to treat said CNS disorder, wherein the area under the serum concentration versus time cu...

The present invention relates to a process for preparing Ziprasidone of formula Ior a pharmaceutically acceptable salt or a solvate or a hydrate thereof;comprising the steps of reacting 1-(12-benzisothiazol-3-yl) piperazine of formula II or its salt:with 5-(2-haloethyl)-6-chloro-oxindole of formula III:wherein X is leaving groups like fluoro chloro bromo iodo or sulphonyl;in the presence of a dispersing agent and a base in a solvent to form ziprasidone of formula I; and optionally converting the...

The present invention provides methods dosage forms and kits for treating with an effective amount of ziprasidone a CNS disorder in a human when the human is in a fasted state. In one embodiment the invention relates to a method for treating a CNS disorder in a human which method comprises administering to the human in a fasted state a solid oral dosage form comprising an amount of ziprasidone effective to treat said CNS disorder wherein the area under the serum concentration versus time curve (...

PURPOSE: A ziprasidone hydrochloride 1.5 hydrate with novel crystal and a method for preparing the same are provided to ensure 99.5% or more of crystal purity and high stability. CONSTITUTION: A method for preparing crystalline ziprasidone hydrochloride 1.5 hydrate comprises: a step of recrystalizing ziprasidone base in a solvent containing 1-methyl-2-pyrrolidone or dimethylsulfoxide; a step of adding t-butylmethyl ether buthylmethyl ether and sec-butylmethyl ether or mixture thereof to prepare ...

The present invention provides methods dosage forms and kits for treating with an effective amount of ziprasidone a CNS disorder in a human when the human is in a fasted state. In one embodiment the invention relates to a method for treating a CNS disorder in a human which method comprises administering to the human in a fasted state a solid oral dosage form comprising an amount of ziprasidone effective to treat said CNS disorder wherein the area under the serum concentration versus time curve (...

Disclosed is an injectable depot pharmaceutical formulation comprising a) a pharmaceutically effective amount of ziprasidone free base or a pharmaceutically acceptable salt thereof which is in the form of nanoparticles having an average particle size of less than about 2000 nm; b) a pharmaceutically acceptable carrier; and c) at least two surface stabilizers; wherein at least one of the surface stabilizers is adsorbed on the surface of the nanoparticles and wherein the combined amount of the sur...